CoChat
Sign Up
Cited by 221

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches

Lang, Frederick M., Lee, Kevin M.-C., Teijaro, John R., Becher, Burkhard, Hamilton, John A.·2020·Nature Reviews Immunology
DOI 10.1038/s41577-020-0357-7PMC PMC7309428
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41577-020-0357-7

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 78

  1. Hamilton, J. A. GM-CSF in inflammation. J. Exp. Med. 217, e20190945 (2020). · DOI · Paper page
  2. Hamilton, J. A., Cook, A. D. & Tak, P. P. Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat. Rev. Drug. Discov. 16, 53–70 (2016). · DOI
  3. Humanigen. FDA approves initiation of Humanigen’s phase III study of lenzilumab in COVID-19 patients. Humanigen https://www.humanigen.com/press/FDA-Approves-Initiation-of-Humanigen%E2%80%99s-Phase-III-Study-of-Lenzilumab-in-COVID-19-Patients (2020).
  4. Wiktor-Jedrzejczak, W. et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (Op/Op) mouse. Proc. Natl Acad. Sci. USA 87, 4828–4832 (1990). · DOI · Paper page
  5. Lieschke, G. J. et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84, 1737–1746 (1994). · DOI
  6. Stanley, E. et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl Acad. Sci. USA 91, 5592–5596 (1994). · DOI
  7. Becher, B., Tugues, S. & Greter, M. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity 45, 963–973 (2016). · DOI
  8. Guilliams, M. et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 210, 1977–1992 (2013). · DOI
  9. Trapnell, B. C. et al. Pulmonary alveolar proteinosis. Nat. Rev. Dis. Prim. 7, 16 (2019). · DOI
  10. Uchida, K. et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N. Engl. J. Med. 356, 567–579 (2007). · DOI
  11. Unkel, B. et al. Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. J. Clin. Invest. 122, 3652–3664 (2012). · DOI
  12. Zhang, J. et al. A novel subset of helper T cells promotes immune responses by secreting GM-CSF. Cell Death Differ. 20, 1731–1741 (2013). · DOI
  13. Croxford, A. L., Spath, S. & Becher, B. GM-CSF in neuroinflammation: licensing myeloid cells for tissue damage. Trends Immunol. 36, 651–662 (2015). · DOI
  14. Cao, Y. et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci. Transl Med. 7, 287ra74 (2015). · DOI
  15. Feldmann, M. et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 395, 1407–1409 (2020). · DOI
  16. Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034 (2020). · DOI · Paper page
  17. Reynolds, G. et al. Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Ann. Rheum. Dis. 75, 899–907 (2016). · DOI
  18. Reghunathan, R. et al. Expression profile of immune response genes in patients with severe acute respiratory syndrome. BMC Immunol. 6, 2 (2005). · DOI
  19. Matute-Bello, G. et al. Neutrophil apoptosis in the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 156, 1969–1977 (1997). · DOI
  20. Ahmed, O. CAR-T-cell neurotoxicity: hope is on the horizon. Blood 133, 2114–2116 (2019). · DOI
  21. Gupta, S. & Weitzman, S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev. Clin. Immunol. 6, 137–154 (2010). · DOI
  22. Tugues, S. et al. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. Sci. Transl Med. 10, eaat8410 (2018). · DOI
  23. Molfino, N. A. et al. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open 6, e00709 (2016). · DOI
  24. Anzai, A. et al. The infarcted myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes. J. Exp. Med. 214, 3293–3310 (2017). · DOI
  25. Cid, M. C. et al. GM-CSF pathway signature identified in temporal artery biopsies of patients with giant cell arteritis [Abstract 2689]. ACR Meeting Abstracts https://acrabstracts.org/abstract/gm-csf-pathway-signature-identified-in-temporal-artery-biopsies-of-patients-with-giant-cell-arteritis/ (2019). · DOI
  26. Spath, S. et al. Dysregulation of the cytokine GM-CSF induces spontaneous phagocyte invasion and immunopathology in the central nervous system. Immunity 46, 245–260 (2017). · DOI
  27. Huang, H. et al. High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study. Cell Mol. Immunol. 16, 602–610 (2019). · DOI
  28. Marinoni, B., Ceribelli, A., Massarotti, M. S. & Selmi, C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto. Immun. Highlights 5, 9–19 (2014). · DOI
  29. Guo, X. et al. Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis. Int. J. Rheum. Dis. 22, 646–653 (2019). · DOI
  30. Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323, 1239–1242 (2020). · DOI · Paper page
  31. Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529–539 (2017). · DOI · Paper page
  32. Siddiqi, H. K. & Mehra, M. R. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J. Heart Lung Transplant. 39, 405–407 (2020). · DOI
  33. Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1017 (2020). · DOI · Paper page
  34. Troyer, E. A., Kohn, J. N. & Hong, S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav. Immun. https://doi.org/10.1016/j.bbi.2020.04.027 (2020). · DOI · Paper page
  35. Rosler, B. & Herold, S. Lung epithelial GM-CSF improves host defense function and epithelial repair in influenza virus pneumonia-a new therapeutic strategy? Mol. Cell Pediatr. 3, 29 (2016). · DOI
  36. Paine, R. III. et al. Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury. Am. J. Pathol. 163, 2397–2406 (2003). · DOI
  37. Baleeiro, C. E. et al. GM-CSF and the impaired pulmonary innate immune response following hyperoxic stress. Am. J. Physiol. Lung Cell Mol. Physiol. 291, L1246–L1255 (2006). · DOI
  38. Matute-Bello, G. et al. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit. Care Med. 28, 1–7 (2000). · DOI
  39. Paine, R. III. et al. A randomized trial of recombinant human GM-CSF for patients with acute lung injury. Crit. Care Med. 40, 90–97 (2012). · DOI
  40. Herold, S. et al. Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 189, 609–611 (2014). · DOI
  41. Subramaniam, R. et al. Delivery of GM-CSF to protect against influenza pneumonia. PLoS One 10, e0124593 (2015).
  42. Sever-Chroneos, Z. et al. GM-CSF modulates pulmonary resistance to influenza A infection. Antivir. Res. 92, 319–328 (2011). · DOI
  43. Steinwede, K. et al. Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia. J. Immunol. 187, 5346–5356 (2011). · DOI
  44. Standiford, L. R. et al. TLR4-dependent GM-CSF protects against lung injury in Gram-negative bacterial pneumonia. Am. J. Physiol. Lung Cell Mol. Physiol. 302, L447–L454 (2012). · DOI
  45. Huang, H., Li, H., Zhou, P. & Ju, D. Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 influenza virus-induced pneumonia in mice. Cytokine 51, 151–157 (2010). · DOI
  46. Halstead, E. S. et al. GM-CSF overexpression after influenza a virus infection prevents mortality and moderates M1-like airway monocyte/macrophage polarization. Respir. Res. 5, 3 (2018). · DOI
  47. Umstead, T. M. et al. Lower respiratory tract delivery, airway clearance, and preclinical efficacy of inhaled GM-CSF in a postinfluenza pneumococcal pneumonia model. Am. J. Physiol. Lung Cell Mol. Physiol. 318, L571–L579 (2020). · DOI
  48. Ballinger, M. N. et al. Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with Pseudomonas aeruginosa. Am. J. Respir. Cell Mol. Biol. 34, 766–774 (2006). · DOI
  49. Cakarova, L. et al. Macrophage tumor necrosis factor-alpha induces epithelial expression of granulocyte-macrophage colony-stimulating factor: impact on alveolar epithelial repair. Am. J. Respir. Crit. Care Med. 180, 521–532 (2009). · DOI
  50. Huffman Reed, J. A. et al. GM-CSF enhances lung growth and causes alveolar type II epithelial cell hyperplasia in transgenic mice. Am. J. Physiol. 273, L715–L725 (1997).
  51. Summers, C. et al. Pulmonary retention of primed neutrophils: a novel protective host response, which is impaired in the acute respiratory distress syndrome. Thorax 69, 623–629 (2014). · DOI
  52. Potey, P. M. D., Rossi, A. G., Lucas, C. D. & Dorward, D. A. Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential. J. Pathol. 247, 672–685 (2019). · DOI
  53. Kudlak, K., DeMuro, J. P., Hanna, A. F. & Brem, H. Acute lung injury following the use of granulocyte-macrophage colony-stimulating factor. Int. J. Crit. Illn. Inj. Sci. 3, 279–281 (2013). · DOI
  54. De Alessandris, S. et al. Neutrophil GM-CSF receptor dynamics in acute lung injury. J. Leukoc. Biol. 105, 1183–1194 (2019). · DOI
  55. Huang, C. et al. Clinical features of patients with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020). · DOI · Paper page
  56. Stienne, C. et al. Foxo3 transcription factor drives pathogenic T helper 1 differentiation by inducing the expression of Eomes. Immunity 45, 774–787 (2016). · DOI
  57. Oh, S. A. et al. Foxp3-independent mechanism by which TGF-β controls peripheral T cell tolerance. Proc. Natl Acad. Sci. USA 114, E7536–E7544 (2017). · DOI
  58. Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697–709 (2019). · DOI
  59. Khameneh, H. J., Isa, S. J., Min, L., Nih, F. W. & Ruedl, C. GM-CSF signalling boosts dramatically IL-1 production. PLoS One 6, e23025 (2011). · DOI
  60. Krebs, J. et al. Intravenous delivery of granulocyte-macrophage colony stimulating factor impairs survival in lipopolysaccharide-induced sepsis. PLoS One 14, e0218602 (2019).
  61. Puljic, R. et al. Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. Eur. J. Pharmacol. 557, 230–235 (2007). · DOI
  62. Bozinovski, S., Jones, J. E., Vlahos, R., Hamilton, J. A. & Anderson, G. P. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. J. Biol. Chem. 277, 42808–42814 (2002). · DOI
  63. Willart, M. A. et al. Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J. Exp. Med. 209, 1505–1517 (2012). · DOI
  64. Shiomi, A. et al. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J. Immunol. 193, 849–859 (2014). · DOI
  65. Sheih, A., Parks, W. C. & Ziegler, S. F. GM-CSF produced by the airway epithelium is required for sensitization to cockroach allergen. Mucosal Immunol. 10, 705–715 (2017). · DOI
  66. Kwon, O. C. et al. IL-17A+GM-CSF+ neutrophils are the major infiltrating cells in interstitial lung disease in an autoimmune arthritis model. Front. Immunol. 9, 1544 (2018). · DOI
  67. Nobs, S. P., Kayhan, M. & Kopf, M. GM-CSF intrinsically controls eosinophil accumulation in the setting of allergic airway inflammation. J. Allergy Clin. Immunol. 143, 1513–1524.e2 (2019). · DOI
  68. Sonderegger, I. et al. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J. Exp. Med. 205, 2281–2294 (2008). · DOI
  69. Verdoni, L. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet https://doi.org/10.1016/S0140-6736(20)31103-X (2020). · DOI
  70. Stock, A. T., Hansen, J. A., Sleeman, M. A., McKenzie, B. S. & Wicks, I. P. GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. J. Exp. Med. 213, 1983–1998 (2016). · DOI
  71. Channappanavar, R. et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 19, 181–193 (2016). · DOI
  72. Cavalli, G. et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30127-2 (2020). · DOI
  73. Weinblatt, M. E. et al. A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis. Arthritis Rheumatol. 70, 49–59 (2018). · DOI
  74. Taylor, P. C. et al. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Res. Ther. 21, 101 (2019). · DOI
  75. Ishii, K. et al. Tocilizumab-refractory cytokine release syndrome (CRS) triggered by chimeric antigen receptor (CAR)-transduced T cells may have distinct cytokine profiles compared to typical CRS. Blood 128, 3358 (2016). · DOI
  76. Sentman, M. L. et al. Mechanisms of acute toxicity in NKG2D chimeric antigen receptor T cell-treated mice. J. Immunol. 197, 4674–4685 (2016). · DOI
  77. Burmester, G. R. et al. Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis. Arthritis Rheumatol. 70, 679–689 (2018). · DOI
  78. Piccoli, L. et al. Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat. Commun. 6, 7375 (2015). · DOI

Cited by

Metadata

Authors
Lang, F. M., Lee, K. M.-C., Teijaro, J. R., Becher, B., & Hamilton, J. A.
ORCID
Venue
Nature Reviews Immunology
Publisher
Springer Science and Business Media LLC
Published
2020-06-23
Volume
20
Issue
8
Pages
507-514
ISSN
  • 1474-1733
  • 1474-1741
DOI
10.1038/s41577-020-0357-7
PMC
PMC7309428
Cited by
221
References
11
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review